Key facts
- This page summarizes Andrew Spaventa's Form 4 filing for Aspen Neuroscience, Inc. (ASPE).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2026, 21:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Conversion of derivative security
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Conversion of derivative security
Additional SEC filing notes
Footnote F1
Each share of Series Seed Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
Footnote F2
Securities held by Axon Holdings, LLC Series XIII - Aspen Seed, of which Mr. Spaventa is a managing partner.
Footnote F3
Securities held by Axon Holdings, LLC Series XXI - Aspen C, of which Mr. Spaventa is a managing partner.
Footnote F4
Shares of Common Stock held by The Andrew K. Spaventa Living Trust Dated April 9, 2014.